Furthermore, DRD2 expression in pancreatic cancer patients is increased, and DRD2-related blockers can inhibit activation of the ERK signaling pathway, thereby limiting tumor progression [14]. The gene discussed is DRD2; the disease is familial pancreatic carcinoma.